慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化*

doi:10.3969/j.issn.1672-5069.2018.05.009

摘要/Abstract

摘要： 目的调查慢性丙型肝炎（CHC）和丙型肝炎肝硬化（LC）患者外周血辅助性T淋巴细胞17（Th17）、调节性T淋巴细胞（Treg）及其相关细胞因子水平的变化。方法 2014年10月~2016年10月本院收治的CHC患者33例,丙型肝炎肝硬化患者27例和健康体检者30例。给予CHC患者α-干扰素联合利巴韦林(PR)方案治疗12 m。采用ELISA法检测白介素-6 （IL-6）、IL-10、IL-17和转化生长因子-β（TGF-β）,使用流式细胞仪检测外周血Th17和CD4⁺CD25⁺Foxp3⁺Treg细胞数。结果 LC和CHC患者外周血Th17和Treg细胞比率和Th17/Treg比值分别为（4.6±0.7）%、（2.7±0.5）%和（1.6±0.4）,和（5.8±0.9）%、（3.1±0.6）%和（1.9±0.5）,均显著高于健康人[（2.3±0.4）%、（1.7±0.4）%和（1.4±0.2）,P<0.05],LC患者外周血Th17和Treg细胞比率和Th17/Treg比值显著高于CHC患者（P<0.05）;LC和CHC患者血清IL-6、IL-10、IL-17和TGF-β水平分别为（9.9±2.5）ng/L、（18.0±3.2） ng/L、（15.3±2.8） ng/L和（5.5±0.8） ng/L,和（14.1±3.0） ng/L、（21.4±4.0） ng/L、（23.3±3.9）ng/L和（7.2±1.2）ng/L,显著高于健康人[（6.7±1.1） ng/L、（14.2±2.9） ng/L、（5.3±0.6） ng/L和（4.3±1.0） ng/L,P<0.05],LC患者血清IL-6、IL-10、IL-17和TGF-β水平显著高于CHC患者（P<0.05）;CHC患者治疗后外周血Th17和Treg细胞比率及血清TGF-β、IL-10和IL-17水平分别为（3.4±0.6）%、（1.9±0.4）%、（4.7±0.6） ng/L、（15.1±2.5） ng/L和（11.5±2.1） ng/L,均显著低于治疗前,差异有统计学意义（t=7.477、t=7.177、t=4.596、t=4.102、t=6.237,P<0.05）。结论 CHC和丙型肝炎肝硬化患者外周血Th17和Treg细胞比率增高,相关细胞因子水平也升高,可能参与了丙型肝炎病毒感染的发病过程,在抗病毒治疗后血清细胞因子水平降低,可能有助于对疗效的观察。

关键词: 肝硬化, 慢性丙型肝炎, 辅助性T淋巴细胞17, 调节性T淋巴细胞, 细胞因子

Abstract: Objective To investigate the changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C（CHC） and liver cirrhosis（LC）. Methods 33 patients with CHC, 27 with CHC-induced LC patients and 30 healthy persons were recruited in this study between October 2014 and October 2016. The patients with CHC received PR therapy for 12 months. The percentages of peripheral blood Th17 and CD4⁺CD25⁺Foxp3⁺Treg cells and serum interleukin-6（IL-6）,IL-10,IL-17 and transforming growth factor-β （TGF-β） were detected by FCM and ELISA respectively. Results The percentages of Th17 and Treg cells and the Th17/Treg ratio in patients with LC were （4.6±0.7）%,（2.7±0.5）% and （1.6±0.4）,and in patients with CHC were （5.8±0.9）%,（3.1±0.6）% and （1.9±0.5）, both significantly higher than（2.3±0.4）%,（1.7±0.4）% and（1.4±0.2） in healthy control （P<0.05）,and the percentages of Th17 and Treg cells and the Th17/Treg ratio in patients with LC were significantly higher than those in patients with CHC （P<0.05）;serum levels of IL-6, IL-10,IL-17 and TGF-beta in patients with LC were（9.9±2.5） ng/L,（18.0±3.2） ng/L,（15.3±2.8） ng/L and （5.5±0.8） ng/L and in patients with CHC were （14.1±3.0） ng/L,（21.4±4.0） ng/L,（23.3±3.9） ng/L and （7.2±1.2） ng/L,both significantly higher than （6.7±1.1） ng/L,（14.2±2.9） ng/L,（5.3±0.6） ng/L and （4.3±1.0） ng/L in healthy persons（P<0.05）,and serum IL-6,IL-10,IL-17 and TGF-β levels in patients with LC were significantly higher than those in patients with CHC（P<0.05）;the percentages of Th17 and Treg cells,and serum TGF-β,IL-10 and IL-17 levels in patients with CHC at the end of the treatment weere （3.4±0.6）% and （1.9±0.4）%,and （4.7±0.6） ng/L,（15.1±2.5） ng/L and（11.5±2.1） ng/L,all significantly lower than those before treatment（t=7.477,t=7.177,t=4.596,t=4.102,t=6.237,P<0.05）. Conclusion The blood Th17 and Treg cell numbers and their related serum cytokines in patients with CHC and LC increase,which might be closely related to the pathogenesis of hepatitis C viral infection. The surveillance of the regulatory T lymphocytes and cytokines might be helpful in evaluating antiviral therapy.

Key words: Liver cirrhosis, Hepatitis C, Helper T lymphocytes 17, Regulatory T lymphocytes, Cytokines

周思思, 沈有秀, 李娟, 俞科贤. 慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 689-692.

Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.

参考文献

[1] 丁佩佩,何纲,陈晓华,等. HIV/HCV共感染者外周血辅助性T细胞17和IL-17A水平检测. 实用肝脏病杂志,2015,18(1):30-33.
[2] Geng X,Xue J.Expression of Treg/Th17 cells as well as related cytokines in patients with inflammatory bowel disease. Pak J Med Sci,2016,32(5):1164-1168.
[3] Cabral M S,Santos T,Santos PL,et al. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection.Cytokine,2017,S1043-4666(17):30272-30277.
[4] Myers RP,Shah H,Burak KW,et al.An update on the management of chronic hepatitis C:2015 consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol,2015,29(1):19-34.
[5] Liu B,Wei G,Li Z,et al.Th17/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis B. Int Immunopharmacol,2017,46(1):48-55.
[6] Yu XP,Guo RY,Su ML,et al.Dynamic changes of Treg and Th17 cells and related cytokines closely correlate with the virological and biochemical response in chronic hepatitis B patients undergoing nucleos(t)ide analogues treatment. Hepat Mon,2013,13(12):e15332.
[7] 吴丽蒙. Treg和Th17细胞在慢加急性乙型肝炎肝衰竭发病机制中的作用研究进展. 实用肝脏病杂志,2017,20(5):639-642.
[8] 刘晶晶,李庆彦,刘春华. 不同病因肝衰竭患者外周血单个核细胞HLA-DR基因水平及血Th17和CD4+CD25+Treg细胞百分比的变化. 实用肝脏病杂志,2015,18(6):598-602.
[9] Feng TT,Zou T,Wang X,et al.Clinical significance of changes in the Th17/Treg ratio in autoimmune liver disease. World J Gastroenterol,2017,23(21):3832-3838.
[10] Lan YT,Fan XP,Fan YC,et al.Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value. Medicine,2017,96(32):e7704.
[11] Xiang M,Guo L,Ma Y,et al.Expression of Th17 and CD4(+) CD25(+) T regulatory cells in peripheral blood of acute leukemia patients and their prognostic significance. Pak J Pharm Sci,2017,30(2(Suppl 1):619-624.
[12] Wang JM,Ma CJ,Li GY,et al.Tim-3 alters the balance of IL-12/IL-23 and drives TH 17 cells:Role in hepatitis B vaccine failure during hepatitis C infection. Vaccine,2013,31(18):2238-2245.
[13] Bruno R,Sacchi P,Puoti M,et al.Pathogenesis of liver damage in HCV-HIV patients. AIDS Rev,2015,10(1):15-24.
[14] Rios DA,Valva P,Casciato PC,et al.Chronic hepatitis C liver microenvironment:role of the Th17/Treg interplay related to fibrogenesis. Sci Rep,2017,7(1):13283.
[15] Hao C,Zhou Y,He Y,et al.Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Immunology,2014,143(4):531-538.
[16] Gao Y,Zhang M,Li J,et al.Circulating FoxP3+ regulatory T and interleukin17-producing Th17 cells actively influence HBV clearance in de novo hepatitis B virus infected patients after orthotopic liver transplantation. Plos One,2015,10(9):e0137881.[17] 王国戗,王小方,汪磊,等. Th17和Treg细胞以及其相关细胞因子在慢性丙型肝炎以及丙型肝炎肝硬化病人外周血中的变化及意义. 中国免疫学杂志,2016,32(6):882-886.
[18] Li X,Su Y,Hua X,et al.Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis. J Transl Med,2017,15(1):75.
[19] Fernández-Rodríguez A,Rallón N,Berenguer J,et al.Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Aids,2013,27(2):163-173.
[20] Behfarjam F,Sanati MH,Nasseri MS,et al.Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis. Turk J Gastroenterol,2017,28(2):110-114.
[21] Wang G,Yang C,Yue D,et al.The changes and its significance of Th17 and Treg cells and related cytokines in patients with tuberculosis pleurisy. Allergy Asthma Clin Immunol,2014,10(1):28.
[22] Tahvili S,Zandieh B,Amirghofran Z.The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis. Int J Dermatol,2015,54(7):e254-e260.
[23] Liang XS,Li CZ,Ying Z,et al.Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. BMC Gastroenterol,2012,12(1):43.
[24] Guo CH,Han LX,Wan MR,et al.Immunomodulatory effect of bone marrow mesenchymal stem cells on T lymphocytes in patients with decompensated liver cirrhosis. Genet Mol Res,2015,14(2):7039-7046.
[25] Asarat M,Apostolopoulos V,Vasiljevic T,et al.Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells in vitro. Immunol Invest,2016,45(3):205-222.
[26] Li J,Qiu SJ,She WM,et al.Significance of the balance between regulatory T(Treg) and T helper 17(Th17) cells during hepatitis B virus related liver fibrosis. Plos One,2012,7(6):e39307.

慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化^*

Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[4]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[5]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[6]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[9]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[12]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[13]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[14]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[15]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.